1. Home
  2. SMID vs LCTX Comparison

SMID vs LCTX Comparison

Compare SMID & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SMID
  • LCTX
  • Stock Information
  • Founded
  • SMID 1960
  • LCTX 1990
  • Country
  • SMID United States
  • LCTX United States
  • Employees
  • SMID N/A
  • LCTX N/A
  • Industry
  • SMID Building Materials
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SMID Industrials
  • LCTX Health Care
  • Exchange
  • SMID Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • SMID 192.2M
  • LCTX 171.8M
  • IPO Year
  • SMID 1995
  • LCTX N/A
  • Fundamental
  • Price
  • SMID $37.87
  • LCTX $0.94
  • Analyst Decision
  • SMID
  • LCTX Strong Buy
  • Analyst Count
  • SMID 0
  • LCTX 3
  • Target Price
  • SMID N/A
  • LCTX $5.67
  • AVG Volume (30 Days)
  • SMID 36.1K
  • LCTX 299.1K
  • Earning Date
  • SMID 11-07-2024
  • LCTX 11-07-2024
  • Dividend Yield
  • SMID N/A
  • LCTX N/A
  • EPS Growth
  • SMID N/A
  • LCTX N/A
  • EPS
  • SMID 0.87
  • LCTX N/A
  • Revenue
  • SMID $68,434,000.00
  • LCTX $6,186,000.00
  • Revenue This Year
  • SMID N/A
  • LCTX N/A
  • Revenue Next Year
  • SMID N/A
  • LCTX $119.00
  • P/E Ratio
  • SMID $44.03
  • LCTX N/A
  • Revenue Growth
  • SMID 26.77
  • LCTX N/A
  • 52 Week Low
  • SMID $17.76
  • LCTX $0.77
  • 52 Week High
  • SMID $48.87
  • LCTX $1.61
  • Technical
  • Relative Strength Index (RSI)
  • SMID 63.26
  • LCTX 55.33
  • Support Level
  • SMID $34.13
  • LCTX $0.87
  • Resistance Level
  • SMID $38.55
  • LCTX $0.94
  • Average True Range (ATR)
  • SMID 2.60
  • LCTX 0.05
  • MACD
  • SMID 0.61
  • LCTX 0.01
  • Stochastic Oscillator
  • SMID 93.07
  • LCTX 92.20

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: